.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Healthtrust
McKesson
Merck
Harvard Business School
Express Scripts
Argus Health
Daiichi Sankyo
Chubb
UBS

Generated: November 19, 2017

DrugPatentWatch Database Preview

Bristol-myers Squibb Company Profile

« Back to Dashboard

What is the competitive landscape for BRISTOL-MYERS SQUIBB, and when can generic versions of BRISTOL-MYERS SQUIBB drugs launch?

BRISTOL-MYERS SQUIBB has three approved drugs.

There are eight US patents protecting BRISTOL-MYERS SQUIBB drugs.

There are three hundred patent family members on BRISTOL-MYERS SQUIBB drugs in forty-nine countries and forty-eight supplementary protection certificates in fourteen countries.

Summary for Bristol-myers Squibb

International Patents:300
US Patents:8
Tradenames:3
Ingredients:3
NDAs:3
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol-myers Squibb
DAKLINZA
daclatasvir dihydrochloride
TABLET;ORAL206843-002Jul 24, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Bristol-myers Squibb
DAKLINZA
daclatasvir dihydrochloride
TABLET;ORAL206843-002Jul 24, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Bristol-myers Squibb
DAKLINZA
daclatasvir dihydrochloride
TABLET;ORAL206843-002Jul 24, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Bristol-myers Squibb
DAKLINZA
daclatasvir dihydrochloride
TABLET;ORAL206843-003Apr 13, 2016RXYesNo► Subscribe► SubscribeY ► Subscribe
Bristol-myers Squibb
DAKLINZA
daclatasvir dihydrochloride
TABLET;ORAL206843-002Jul 24, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Bristol-myers Squibb
DAKLINZA
daclatasvir dihydrochloride
TABLET;ORAL206843-001Jul 24, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Bristol-myers Squibb
DAKLINZA
daclatasvir dihydrochloride
TABLET;ORAL206843-001Jul 24, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Bristol-myers Squibb
DAKLINZA
daclatasvir dihydrochloride
TABLET;ORAL206843-001Jul 24, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Bristol-myers Squibb
EVOTAZ
atazanavir sulfate; cobicistat
TABLET;ORAL206353-001Jan 29, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Bristol-myers Squibb
DAKLINZA
daclatasvir dihydrochloride
TABLET;ORAL206843-002Jul 24, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Bristol-myers Squibb

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol-myers Squibb
VIDEX
didanosine
FOR SOLUTION;ORAL020156-001Oct 9, 1991► Subscribe► Subscribe
Bristol-myers Squibb
VIDEX
didanosine
FOR SOLUTION;ORAL020156-001Oct 9, 1991► Subscribe► Subscribe
Bristol-myers Squibb
VIDEX
didanosine
FOR SOLUTION;ORAL020156-001Oct 9, 1991► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Bristol-myers Squibb

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,383,655Modulators of pharmacokinetic properties of therapeutics► Subscribe
6,110,946 Antivirally active heterocyclic azahexane derivatives► Subscribe
7,939,553Modulators of pharmacokinetic properties of therapeutics► Subscribe
8,303,944Hepatitis C virus inhibitors► Subscribe
8,846,023Hepatitis C virus inhibitors► Subscribe
9,758,487Hepatitis C virus inhibitors► Subscribe
8,088,770Modulators of pharmacokinetic properties of therapeutics► Subscribe
6,300,519 Antivirally active heterocyclic azahexane derivatives► Subscribe
8,486,942Modulators of pharmacokinetic properties of therapeutics► Subscribe
9,227,961Hepatitis C virus inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Bristol-myers Squibb Drugs

Country Document Number Estimated Expiration
South Korea20150042869► Subscribe
HungaryE029843► Subscribe
TaiwanI359813► Subscribe
Portugal900210► Subscribe
Netherlands300713► Subscribe
Japan2009102357► Subscribe
Norway2017002► Subscribe
Lithuania2487161► Subscribe
Germany122005000003► Subscribe
Poland2784075► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Bristol-myers Squibb Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0713Netherlands► SubscribePRODUCT NAME: DACLATASVIR EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN, IN HET BIJZONDER DACLATASVIR DIHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/939/001-004 20140826
00713Netherlands► SubscribePRODUCT NAME: DACLATASVIR EN FARMACEUTISCH; REGISTRATION NO/DATE: EU/1/14/939/001-004 20150119
189Luxembourg► Subscribe91189, EXPIRES: 20190302
/2016Austria► SubscribePRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON UND ATAZANAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE ATAZANAVIR-SULFAT; REGISTRATION NO/DATE: EU/1/15/1025 (MITTEILUNG) 20150715
2016000104Germany► SubscribePRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON UND TENOFOVIRALAFENAMID ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/15/1061 20151119
2016000120Germany► SubscribePRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCHES AKZEPTABLES SALZ DAVON UND ATAZANAVIR ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE ATAZANAVIRSULFAT; REGISTRATION NO/DATE: EU/1/15/1025 20150713
90007-9Sweden► SubscribePRODUCT NAME: DACLATASVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY DACLATASVIR DIHYDROCHLORIDE; REG. NO/DATE: EU/1/14/939 20140826
2015Austria► SubscribePRODUCT NAME: DECLATASVIR; REGISTRATION NO/DATE: EU/1/14/939 (MITTEILUNG) 20140826
864Luxembourg► SubscribePRODUCT NAME: COBICISTAT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; FIRST REGISTRATION DATE: 20130527
2016040Lithuania► SubscribePRODUCT NAME: DARUNAVIRAS + KOBICISTATAS; REGISTRATION NO/DATE: EU/1/14/967 20141119
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Covington
Novartis
Colorcon
Boehringer Ingelheim
Chinese Patent Office
Deloitte
Citi
AstraZeneca
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot